HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2

PURPOSE: Dual blockade of HER2 with trastuzumab and lapatinib or pertuzumab has been shown to be superior to single-agent trastuzumab. However, a significant fraction of HER2-overexpressing (HER2+) breast cancers escape from these drug combinations. In this study, we sought to discover the mechanism...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Hanker, Ariella B., Garrett, Joan T., Estrada, Mónica Valeria, Moore, Preston D., Ericsson, Paula González, Koch, James P., Langley, Emma, Singh, Sharat, Kim, Phillip S., Frampton, Garrett M., Sanford, Eric, Owens, Philip, Becker, Jennifer, Groseclose, M. Reid, Castellino, Stephen, Joensuu, Heikki, Huober, Jens, Brase, Jan C., Majjaj, Samira, Brohée, Sylvain, Venet, David, Brown, David, Baselga, José, Piccart, Martine, Sotiriou, Christos, Arteaga, Carlos L.
Format: Artigo
Sprog:Inglês
Udgivet: 2017
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5540793/
https://ncbi.nlm.nih.gov/pubmed/28381415
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-16-2287
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker